scout
|Articles|March 19, 2016

Novel BTK, PI3K Inhibitors on Horizon for Relapsed CLL

Author(s)Silas Inman

A multitude of PI3K and BTK inhibitors are currently in development that offer distinct advantages over existing treatments for patients with relapsed chronic lymphocytic leukemia.

Susan M. O’Brien, MD

With the onslaught of new PI3K and BTK inhibitors currently in development for patients with relapsed chronic lymphocytic leukemia (CLL), it is challenging to know which therapies are truly “next-generationâ€

Newsletter

Stay up to date on the most recent and practice-changing oncology data


Latest CME